Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trialResearch in context

Summary: Background: Type 2 diabetes (T2DM) remains a challenge to treat despite the expansion of various therapeutic classes. Visepegenatide (PB-119) is a once a week, subcutaneous, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection without the requirement of dose titration that has sho...

Cijeli opis

Bibliografski detalji

Glavni autori:	Xiang Yan, Jianhua Ma, Yan Liu, Xuhong Wang, Sheli Li, Shuang Yan, Zhaohui Mo, Yikun Zhu, Jingna Lin, Jie Liu, Ying Jia, Li Liu, Ke Ding, Michael Xu, Zhiguang Zhou
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-06-01
Serija:	The Lancet Regional Health. Western Pacific
Teme:	Visepegenatide HbA1c Glycaemic control Diabetes BMI GLP-1 RA
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2666606524000956
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!